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Abstract 
  
Nicholas Empey: “Analyzing the Diversity of a Small Antibody Mimic Library” 
(Under the direction of Professor Rihe Liu) 
 
The search for targeting molecules that allow therapies to be site-directed and specific is 
a very important area of research.  Small engineered protein domains are well suited because 
of their size to be utilized as such targeting molecules.  This thesis aims to examine the 
process of directed forward evolution of a small three helix bundle domain (3HB) library.  
mRNA display pre-selection was performed to analyze the 3HB library’s potential to be 
successful in that process.  3HB genes were shown to be expressed at very low levels in 
E.Coli.  Also, sequencing analysis from a pGFP-3HB fusion library is presented. 
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 CHAPTER 1 
Introduction 
Site-directed delivery of therapeutic agents is an important area of research that aims 
to reduce the toxicity and increase the efficacy of said agents.  The use of biologically 
relevant molecules such as proteins and small protein domains are being investigated based 
on their ability to recognize cell-specific markers such as cancer-specific markers, to 
facilitate cell uptake, or to overcome other transport barriers that would normally limit small 
molecule or biopharmaceutical therapies.  Specifically, attachment of these molecules to 
nanoparticles could prove very beneficial to the recognition of diseased cells or foreign 
bodies. 
An important attribute of targeting molecules is size.  Targeting molecules vary 
greatly in size with each presenting a list of benefits and challenges associated with it.  
Figure 1 illustrates the size differences between some currently developed targeting 
molecules.  Small molecules have the advantage of being able to be assembled in great 
numbers on the surface of nanoparticles, but can also lack good binding specificity or affinity 
to extracellular protein targets.  Large proteins such as antibodies or antibody fragments are 
limited as to the number of molecules that be attached to the surface of nanoparticles, but can 
be more specific and bind more strongly to their targets compared with small molecules.  
Somewhere in between these two classes of molecules is another class of molecules called 
engineered protein domains. 
 Figure 1.  The varying size of targeting molecules.  Large molecules (top) such as IgG are much larger than small 
molecules (bottom).  Engineered protein domains fit into the “green” class of molecules comparable in size to 
aptamers, toxins, or peptides.  Image used by permission of Rihe Liu (1). 
 
Engineered protein domains are smaller in size than full-sized antibodies, which 
allows them to be assembled in greater numbers on the surface of nanoparticles and maintain 
target specificity.  These molecules are typically similar to naturally occurring small proteins.  
By randomizing specific amino acids on the surface of the protein domain one can acquire a 
library of molecules each with potentially different protein-binding properties, folding and 
stability profiles, and expression levels in bacteria, etc.  Using a directed evolution method 
such as mRNA display one can select from a large pool of engineered protein domains 
molecules that interact with therapeutically relevant proteins. 
mRNA display 
The process of mRNA display begins with generating a cDNA library, which encodes 
for a desired protein library.  The cDNA is amplified, transcribed, and then conjugated to a 
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short DNA linker, which contains psoralen, an oligo-dA fragment, and puromycin (2).  The 
mRNA is translated in vitro and fused to its mRNA via ribosome incorporation of puromycin 
onto the growing peptide chain.  The fused molecules are purified using oligo-dT resin 
followed by reverse transcription to generate an mRNA/DNA hybrid chain fused to protein.  
The resulting molecules are then purified based on an affinity tag (i.e. His6 or FLAG) 
embedded in the protein, and the hybrid DNA is amplified to regenerate the selected library.  
This process is repeated to select for the desired proteins with the best binding profiles 
against biological protein targets of interest (3).  Figure 2 illustrates this process. 
 
Figure 2.  The mRNA display protein selection process. 
The research presented herein regarding mRNA display only encompasses one round 
of the selection process commonly referred to as pre-selection.  The purpose of performing 
pre-selection in this context was to learn techniques associated with the selection process and 
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to validate the particular library as worthy of undergoing future rounds of selection using the 
mRNA display process. 
Protein Folding Assay 
Another technique that can be used to accompany forward evolution of protein 
libraries is a protein folding assay that utilizes green fluorescent protein (GFP) as a reporter 
(4).  The principle is when GFP is fused to an N-terminal protein and expressed in bacteria, 
the fluorescence of GFP is dependent on stable folding of the upstream protein.  GFP allows 
one to perform a relative analysis of fluorescent intensity in bacterial colonies where more 
fluorescence correlates to a more stably folded protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER 2 
mRNA Display Results 
The original three-helix bundle, aka “tribody” (3HB), library consisted of a coding 
region that when translated would create a His6 tag that could be used for purification of the 
mRNA-display fused proteins.  However, this method proved to be very inefficient at 
purifying the fused molecules.  Therefore, a new library design was undertaken to append a 
region to the 3’ end of the library that when translated would create a FLAG tag that could be 
used for more robust purification. 
The 3HB library consists of a T7 promoter sequence to facilitate efficient in vitro 
transcription by T7 polymerase as well as a flexible 5’ untranslated region that helps to 
facilitate efficient in vitro translation in reticulocyte rich lysate (3).  The open reading frame 
encodes for variable residues using the NNS approach where N = A, T, C, or G and S = G or 
C to minimize the random occurrence of stop codons in the open reading frame.  The His6 tag 
is still intact in addition to the FLAG tag coding region.  At the 3’ end there is a psoralen-
preferred intercalating/binding site, which facilitates UV cross-linking of the library DNA 
with the puromycin linker, and a stop codon at the 3’ terminus, which allows for efficient 
ribosome turnover during translation of non-fused mRNA transcripts. 
Library modification required two steps.  The first step involved annealing the 
library’s original 3’ primer to the original DNA template.  The second step of annealing 
involved annealing the product of the first step with a new 3’ primer to append the FLAG tag 
coding region.  Taq DNA polymerase was used for the extension of both annealing reactions.  
Figures 3 and 4 show the agarose gel results of these two annealing steps.  The theoretical 
diversity of molecules that could be attained from 81.5 pmol of 3HB library is 4.9x1013 
molecules, which assumes 100% efficient annealing and recovery.  Assuming that each 
molecule generated was unique the calculated diversity of the library after purification was 
7.98x1012 molecules.  In reality this number could be much lower. 
 
0     5     8    10   12    15 
200 bp 
Figure 3.  First step annealing optimization.  8 cycles optimal. 
                    
0      5       8     10   13 
0      5     8    10  12 200 bp
a. 
200 bp 
b. 
Figure 4. Second step annealing optimization.  a. Double banding observed.  b. No double banding observed. 
After library modification polymerase chain reaction (PCR) using Taq polymerase 
(NEB) was employed to amplify the resulting library.  Based on the calculated diversity and 
the final yield of 634.5 pmol of the amplified library, there were 47 copies of each unique 
strand of library DNA.   
The process of mRNA display pre-selection was undertaken by first transcribing the 
3HB library cDNA into mRNA and removing excess cDNA template with DNase enzyme.  
From 40 pmol of cDNA 225.4 pmol of mRNA was recovered after purification according to 
calculations from agarose gel intensity compared to that of the quantitative RNA ladder 
(Figure 5). 
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 cDNA                 mRNA DNase digested   Cross-linked 
300 bp
Figure 5.  Transcribed mRNA before and after DNase digestion and cross-linked with the P-linker. 
The mRNA was then annealed to a DNA linker that contained psoralen on its 5’ end 
and puromycin on its 3’ end.  To conjugate this P-linker to the mRNA the reaction tube was 
subjected to UV light.  As a nucleotide chain intercalater, psoralen intercalates the mRNA 
and upon exposure to UV light forms a covalent bond with thymine preferentially at the 5’-
TpA site that resides at the 3’ terminus.  This causes the ribosome to stall at the cross-linked 
point and allows the puromycin moiety to be in close proximity to the ribosome during 
translation so that the mRNA can be fused to its protein.  Figure 6 is a schematic of the cross-
linking process.  Assuming that cross-linking efficiency is 40% 38.8 pmol of mRNA was 
cross-linked with the P-linker from an input of 97 pmol. 
 
= psoralen 
= puromycin 
Figure 6.  Psoralen UV cross-linking process diagram. 
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The cross-linked mRNA was then translated in reticulocyte lysate containing yeast 
and calf liver tRNA that recognizes the “rare codons” not normally present in reticulocytes.  
Normal methionine was replaced with radiolabeled 35S-methionine to monitor the efficiency 
of translation and purification in future analysis.  The translated proteins were then 
immediately fused to their mRNA transcripts via puromycin incorporation to the end of the 
peptide chain.  Puromycin acts as a translation terminator via its properties as an 
aminoacylated tRNA mimic (5; 6; 7) effectively fusing the mRNA with its protein.  Fusion 
molecules are difficult to quantify by spectrometry because they are composed essentially of 
two different molecules with different properties, hence the incorporation of 35S-methionine.  
The fusion molecules were visualized via a SDS-PAGE electrophoresis gel (Figure 9 lane 3).  
Because fusion reactions are not 100% efficient free mRNA and free protein 
molecules still existed in the translation reaction mixture.  Oligo dT purification removed the 
free proteins by hybridizing to the poly-dA portion of the DNA linker.  The number of fusion 
molecules remaining were quantified using scintillation and analyzed according to relative 
radioactivity counts.  Figure 7 contains the scintillation counts for oligo dT purification of the 
3HB fusion molecules.  The majority of 35S-methionine gets incorporated into free proteins 
or remains unincorporated and appears in the flowthrough.  Most of the fused product is 
eluted during the first elution, which accounts for 0.06% of the total counts per minute 
(CPM).  Figure 9 (lane 4) shows the fusion molecules present on a SDS-PAGE 
electrophoresis gel after oligo dT purification. 
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 Figure 7.  Oligo dT purification results.  Most of the purified fusion molecules eluted in the first Elution fraction.  
The flowthrough fraction is omitted from the graph for clarity. 
 
The next step was to reverse transcribe the mRNA portion of the fusion molecules so 
that the cDNA can form a duplex with the mRNA and then be amplified using PCR to 
generate a library of in-frame reading sequences that would facilitate further rounds of 
mRNA display selection. 
To remove free mRNA molecules FLAG purification was employed.  The FLAG tag 
sequence, N-DYKDDDDK-C, at the C-terminus of the 3HB protein is recognized by the 
ANTI-FLAG® (M2) affinity gel and provides a handle for affinity purification through a 
filtration column.  The FLAG peptide in the elution buffer displaces the fused molecules that 
are bound to the ANTI-FLAG® (M2) affinity gel, and the fused molecules are eluted in the 
buffer.  Figure 5 contains the scintillation counts for the FLAG-purification of the 3HB fused 
molecules.  The sum of Elutions 1 and 2 equal about 26% of the total CPM.  Much of the 
radioactivity in the flowthrough could be due to out of frame translation of the mRNA 
transcripts, which would lead to an absence of FLAG epitope.  Figure 9 (lane 5) shows the 
presence of fusion molecules on a SDS-PAGE electrophoresis gel after FLAG purification. 
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 Figure 8.  FLAG purification results.  Most of the purified fusion molecules eluted in the first two fractions. 
 
 
1    2     3        4 
80 kD 
Figure 9.  SDS-PAGE gel results for fusion through FLAG purification.  Lane 1: early fusion.  Lane 2: complete 
fusion.  Lane 3: Oligo dT purified.  Lane 4: FLAG purified. 
 
To confirm that the pre-selected library had been properly fused, reverse transcribed, 
and purified, PCR was employed to observe DNA amplification of the reverse transcribed 
DNA.  Unfortunately, amplification was not observed (Figure 6).  However, the presence of 
oligo dT purified and FLAG purified products on the SDS-PAGE gels leads one to believe 
that something was in error during the reverse transcription step.  Because of time constraints 
and the fact that this library was not going to proceed through further rounds of mRNA 
display selection further optimization of the reverse transcription reaction was not pursued.  
However, a couple of approaches could be taken to optimize the reverse transcription step 
and regenerate the 3HB library for future experiments.  One would be to heat the fusion 
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molecule, primer, and dNTP mixture to 65°C for five minutes as recommended by the 
SuperScriptTM II protocol manual (8) before the rest of the reagents are added as outlined in 
the said protocol.  This could facilitate denaturing of the mRNA strand and allow the reverse 
transcription primer easier access to its mRNA template.  Another would be to use the 
freshest dithiothreitol (DTT) available in the reaction.  Upon review of the materials used for 
the experiment described above it was noted that the DTT used had undergone numerous 
freeze/thaw cycles.  SuperScriptTM II is very sensitive to DTT concentration, and since the 
DTT used was not fresh, it’s possible that the effective concentration was well below optimal 
concentration for efficient SuperScriptTM II activity. 
However, the 3HB library lent itself to facile optimization throughout the rest of the 
mRNA display pre-selection process, and it is hypothesized that interesting proteins based on 
the 3HB library scaffold can be discovered through the process of mRNA display. 
 
E1   E2   E4
200 bp
Figure 10.  No PCR amplification of DNA on FLAG purified 3HB library for Elution 1 (E1) or Elution 2 (E2). 
Elution 4 (E4) used as a negative control. 
 
mRNA Display Materials and Methods 
The library was constructed in two steps.  First, 5 pmol of the library’s original 3’ 
primer, TBD-3-122 (5’-TTA ATA GCC GGT GCC AGA TCC AGA CAT TCC CAT AGA 
ACC GCC ATG ATG ATG ATG ATG ATG GCT ACC ACC AGA ACC ACC TTT ACG 
CTG CTC GAA CTC CTC AAA AAA CTG GCG GAT GGC TTC TT-3’), was annealed to 
5 pmol of the original DNA template, 3HB-129 (5’-ATG AAA CAG TGG AGC GAG NNS 
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GTG GAG NNS NNS CTG NNS NNS TTC GTG AAA NNS CAT CAG CGC ATT ACC 
CAG NNS NNS CTG CAT NNS NNS GCC CAG NNS CTG GGT CTG AAT GAA GAA 
GCC ATC CGC CAG-3’) and extended by Taq DNA polymerase (NEB# M0273) under the 
following conditions: 1) 94°C for 2 minutes, 2) 94°C for 2 minutes, 58°C for 1 minute, 72°C 
for 2 minutes (repeating cycle two 16 times), 3) 72°C for 10 minutes.  After checking 
samples taken at various times throughout the reaction and visualizing via electrophoresis on 
a 2% agarose gel it was observed that the conditions were appropriate and eight cycles were 
optimal for the first annealing reaction. 
Second, 5 pmol of the annealed product from step one was annealed to 5 pmol of the 
new 3’ primer, TLLO-L-3-105 (5’-TTA ATA GCC GGT GGA CAT TCC CAT ACC TTT 
GTC GTC GTC GTC CTT GTA GTC GCT GCC GCC CTG GAA ATA CAG ATT TTC 
ACC GCC ATG ATG ATG ATG ATG ATG GCT-3’), which contained the FLAG tag 
coding region.  The conditions used for this reaction were 1) 94°C for 2 minutes, 2) 94°C for 
1 minute, 60°C for 40 seconds, 72°C for 1 minute (repeating cycle two 12 times), 3) 72°C for 
10 minutes.  After analyzing samples taken at different times throughout the reaction by 
visualizing via electrophoresis on a 2% agarose gel a double banding pattern was observed 
instead of the expected single band.  The second annealing step was run again altering the 
annealing temperature in the reaction from 60°C to 62°C.  Less intense double banding was 
observed, and it was observed that eight cycles were optimal for the second step annealing 
reaction. 
After optimization of these two steps large scale annealing was undertaken to achieve 
a high diversity of library molecules.  A total of 81.5 pmol of original 3HB DNA template, 
TBD-3-122, and TLLO-3-105 each were annealed together.  Three separate batches of 
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reactions were run for a total of 815 µL reaction volume.  The reactions were purified using 
QIAgen’s QIAquick PCR Purification Kit (QIAgen# 28104) using the microcentrifuge 
protocol.  The final volume of 125 µL yielded a calculated concentration of 106 nM.  
Concentration was calculated using NIH Image J software (9).  This equates to a diversity of 
7.98x1012 potentially unique molecules of 3HB. 
Optimization for PCR proceeded using 1.25 pmol of annealed library template and 
12.5 pmol of 5’ primer, TBD-5-63 (5’-TTC TAA TAC GAC TCA CTA TAG GGA CAA 
TTA CTA TTT ACA ATT ACA ATG AAA CAG TGG AGC GAG-3’), and 3’ primer, 
TLLO-L-3-105.  The conditions used for this reaction were 1) 94°C for 2 minutes, 2) 94°C 
for 2 minutes, 58°C for 1 minute, 72°C for 2 minutes (repeating cycle two 16 times), 3) 72°C 
for 10 minutes.  After analyzing samples taken at different times throughout the reaction via 
visualization on a 2% agarose gel (Figure 11.a) a double banding pattern was observed 
instead of the expected single band.  To eliminate the presence of the second band a different 
3’ primer, ZL-3-57 (5’-GCG ACT ACA AGG ACG ACG ACG ACA AAG GTA TGG GAA 
TGT CCA CCG GCT ATT AA-3’), which is a small fragment of TLLO-L-3-105, was used 
in the same 12.5 pmol amount.  To further anticipate optimal conditions the annealing 
temperature was raised to 60°C to potentially reduce unspecific amplification.    Samples 
were taken throughout the course of the 16 cycle PCR reaction and visualized and analyzed 
via electrophoresis on a 2% agarose gel (Figure 11.b).  It was observed that 12 cycles was 
optimal for clean and efficient amplification of the library. 
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 0      6      8     10    12    16 
300 bp 300
a. 
 
0          4        6         8        10      12       16 
300 bp 
b. 
Figure 11.  PCR optimization.  a. Double banding pattern observed.  b. No double banding observed. 
After optimization of the PCR reaction step, the library was amplified on a large 
scale.  A total of 4 mL reaction volume was reacted in two batches of 2 mL each, which 
proceeded in 20 PCR strip tubes (VWR# 53509-304) of 100 µL each to generate the final 
amplified product, 3BDLib-PCR-321 (5’-TTC TAA TAC GAC TCA CTA TAG GGA CAA 
TTA CTA TTT ACA ATT ACA ATG AAA CAG TGG AGC GAG NNS GTG GAG NNS 
NNS CTG NNS NNS TTC GTG AAA NNS CAT CAG CGC ATT ACC CAG NNS NNS 
CTG CAT NNS NNS GCC CAG NNS CTG GGT CTG AAT GAA GAA GCC ATC CGC 
CAG TTT TTT GAG GAG TTC GAG CAG CGT AAA GGT GGT TCT GGT GGT AGC 
CAT CAT CAT CAT CAT CAT GGC GGT GAA AAT CTG TAT TTC CAG GGC GGC 
AGC GAC TAC AAG GAC GAC GAC GAC AAA GGT ATG GGA ATG TCC ACC GGC 
TAT TAA-3’).  The reactions were purified using QIAgen’s QIAquick PCR Purification Kit 
using the microcentrifuge protocol.  The 400 µL resulting volume of the first batch of PCR 
yielded a calculated concentration of 838 nM.  The 300 µL resulting volume of the second 
batch yielded a calculated concentration of 997 nM.  Concentrations were calculated using 
NIH Image J software (9).  This equates to approximately 47 copies of each potentially 
unique molecule of 3HB. 
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To begin the process of the mRNA-display pre-selection process the DNA was 
transcribed into mRNA.  60 pmol of the DNA library was reacted with 50 U of T7 RNA 
polymerase (New England Biolabs# M0251S) for a total of 300 µL volume at 37°C for 7 
hours to attain the final transcript mRNA (5’-G GGA CAA UUA CUA UUU ACA AUU 
ACA AUG AAA CAG UGG AGC GAG NNS GUG GAG NNS NNS CUG NNS NNS UUC 
GUG AAA NNS CAU CAG CGC AUU ACC CAG NNS NNS CUG CAU NNS NNS GCC 
CAG NNS CUG GGU CUG AAU GAA GAA GCC AUC CGC CAG UUU UUU GAG 
GAG UUC GAG CAG CGU AAA GGU GGU UCU GGU GGU AGC CAU CAU CAU 
CAU CAU CAU GGC GGU GAA AAU CUG UAU UUC CAG GGC GGC AGC GAC 
UAC AAG GAC GAC GAC GAC AAA GGU AUG GGA AUG UCC ACC GGC UAU 
UAA-3’).  EDTA was added in the amount of two times the molar amount of Mg2+ to the 
reaction, and a sample of the mRNA was analyzed via electrophoresis on a 1.2% agarose gel 
(figure 4).  The reaction mix was then stored at -20°C overnight.  The mRNA was purified by 
adding one volume of acid phenol chloroform pH 4.5, vortexing, centrifuging at 14,000 rpm 
for 10 min at 4°C, and transferring the supernatant to a new tube.  This step was repeated 
once.  One volume of chloroform was then added, the sample was vortexed and centrifuged 
as described above, and the supernatant was transferred to a new tube.  The mRNA was 
desalted by letting the sample elute through a NAP-5 column (GE Healthcare# 17-0853-01) 
according to the protocol included with the column. 
The mRNA was subjected to digestion from DNase enzyme (Promega# M6101) for 4 
hr at 37°C.  EDTA was added in the amount of two times the molar amount of Mg2+ to the 
reaction, and the mRNA was purified using the acid phenol chloroform procedure exactly as 
mentioned above.  After purification 0.5 volume of 7.5 M LiCl was added to the sample, 
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mixed well, and stored at -20°C overnight.  The mRNA sample was concentrated by 
centrifuging the sample at 14,000 rpm for 20 min at 4°C, then discarding the supernatant.  
The precipitate was washed twice with 0.5 mL 70% ethanol and centrifuged at 14,000 rpm 
for 5 min at 4°C followed by removal of the supernatant after each wash.  The mRNA was 
then dried by leaving the open tube in a chemical hood for 8 min.  The mRNA pellet was 
resuspended in 150 µL of water, and the product was visualized via electrophoresis on a 
1.2% agarose gel.  Concentration was calculated using NIH Image J software (9). 
97 pmol of input mRNA was then annealed to 940 pmol of the DNA P-linker (5’-
psoralen-TAG CCG GTG AAA AAA AAA AAA AAA CCA CC-puromycin-3’) in 20 mM 
HEPES pH 7.4 and 100 mM KCl under the following conditions: 75°C for 8 min, 74°C for 
20 sec decreasing 1°C every 20 sec until reaching 35°C, 25°C for 30 min.  The annealed 
products were exposed to 365 nm UV light for 20 min at 4°C in a dark box.  A 0.5 volume of 
7.5 M LiCl was added, and the cross-linked mRNA was stored at -20°C overnight.  The 
resulting cross-linked mRNA was purified and concentrated by centrifuging at 14,000 rpm 
for 20 min at 4°C and pouring off the supernatant.  The pellet was washed twice using 0.5 
mL 70% ethanol and centrifuged at 14,000 rpm for 5 min at 4°C each wash.  The pellet was 
given 10 min to dry in a chemical hood before being resuspended in 50 µL 
diethylpyrocarbonate (DEPC)-treated water.  The cross-linked products were visualized on a 
1.2% agarose gel. 
Assuming that cross-linking efficiency is 40% of the total mRNA concentration, 6.5 
pmol of cross-linked mRNA (RNA-X) was translated using the Retic Lysate IVTTM kit 
(Ambion# AM1200) with buffer lacking methionine plus 60 mM KCl.  36.4 µCi of 
radioactive methionine (35S) (Perkin Elmer# NEG009A005MC) was added to the translation 
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mix.  The 100 µL translation proceeded for 90 min at 30°C.  Afterwards the reaction was 
allowed to cool to room temperature for 5 min, then 105.6 mol KCl and9.1 mol MgCl2 was 
added to the reaction to facilitate faster fusion of the peptide chain with the puromycin.  The 
translation reaction mixture was kept at room temperature for 1 hr then stored at -20°C 
overnight.  The fusion molecules were visualized on a 10% SDS-PAGE gel that was then 
placed in an exposure cassette against a phosphor screen (Molecular Dynamics Low Energy 
Screen) for imaging (Figure 9).  
60 mg of oligo dT cellulose powder (Ambion# AM10020) was prepared by washing 
it three times with 1 mL DEPC-treated water and twice with 1 mL oligo dT binding buffer 
(10x STE [Fisher# BP2478-1; 100 mM NaCl, 1 mM EDTA, and 10 mM Tris pH 8.0] and 
Triton-X [0.2%]) being centrifuged at 3500 rpm for 2 min and the supernatant being removed 
after each wash.  With 1 mL oligo dT binding buffer the oligo dT cellulose powder was 
transferred to a 15 mL tube.  The 100 µL translation reaction was added to the powder along 
with 8.5 mL oligo dT binding buffer and 10 mol of DTT.  The cap was sealed and the tube 
wrapped in aluminum foil to be rotated at 4°C for 2 hr.  A Biorad polyprep column (Biorad# 
731-1550) was used to elute the flowthrough.  The oligo dT powder was washed once with 1 
mL the binding buffer, twice with 1.25 mL binding buffer, and once with 0.625 mL.  The 
oligo dT powder was then washed four times with 1.25 mL wash buffer that consisted of 2 M 
KCl, 1 M Tris pH 8.0, and Tween-20 (0.05%).  The fusion molecules were then eluted four 
times with 0.7 mL DEPC-treated water.  The amount of fusion molecules eluted was 
measured by a scintillation counter to assess the level of radioactivity in 1% of each sample.  
The product was also visualized on a 10% SDS-PAGE gel that was then placed in an 
exposure cassette against a phosphor screen for imaging (Figure 9). 
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Half (350 µL) of the oligo dT purified fusion molecules taken from Elution 1 were 
reacted with 1 mmol of the reverse transcription primer ZLRT (5’-TTT TTT TTT TNN GAC 
ATT CCC ATA CCT TTG TC-3’) and 3000 units of SuperScriptTM II (Invitrogen# 18064) in 
reaction buffer containing 5 mol of DTT.  ZLRT was added to the eluate and incubated at 
room temperature for 15 min.  Then, the reaction buffer, dNTPs, and DTT were added, and 
the reaction was incubated at 42°C for 2 min.  Then, SuperScriptTM II was added, and the 
reaction was incubated at 42°C for 50 min.  At the conclusion of the reaction time 3.16 mol 
of EDTA was added to the reaction mixture.  The storage buffer was changed to TBST (1M 
Tris pH 7.5, 5 M NaCl, and Tween-20 [0.05%]) using a NAP-5 column (GE Healthcare# 17-
0853-01). 
To begin FLAG purification 400 µL of ANTI-FLAG® (M2) affinity gel (Sigma-
Aldrich®# A2220) was placed in a 10 mL polyprep column (Biorad# 731-1550) and was 
washed five times with 1 mL of 100 mM glycine pH 3.5.  It was then washed three times 
with 8 mL TBST buffer.  1 mL of the reverse transcription reaction mix was added to the 
column and the column was rotated while capped at 4°C for 2 hr at an angle as to prevent the 
gel and mixture from sticking to the upper wall of the column.  The flow through was 
collected and reloaded to the column three times.  The fusion molecules were eluted from the 
gel four times with 0.125 mg FLAG peptide in 500 µL TBST for each elution.  Each of the 
four elutions was rotated while in the column for 30 min at 4°C.  Scintillation counting 
measured the radioactivity of 1% of the elutions. 
Using the same conditions as the initial library PCR amplification 5 µL of FLAG 
purification elutions 1, 2, and 4 were reacted in 50 µL reactions using Taq polymerase.  The 
same forward and reverse primers were used as the initial amplification of the 3HB library. 
 CHAPTER 3 
Gene Expression Results 
In vivo expression in bacteria of selected 3HB genes is desirable for obtaining large 
amounts of the protein.  Typically bacterial expression optimization would be performed 
after mRNA display has selected a set of genes that when expressed have good protein 
binding partners.  Because mRNA display selection was not performed in its entirety a set of 
genes was chosen from gene sequencing results.   
Following amplification of the library the sequences of the replicated transcripts were 
screened to ensure their quality.  The PCR product was cloned into pJET1.2/blunt vector and 
was grown in Top10 E.Coli cells.  96 genes were screened by colony PCR for correct length 
and sequenced at Beckman Coulter Genomics (Danvers, MA).  40% of the sequences 
contained full-length genes, and 77% of those gene sequences contained no stop codons at 
variable positions.  All sequences were unique and therefore reinforced the diversity of the 
library.  Eight sequences were chosen from the plate of 96 sequenced colony PCR reactions.  
These eight genes were digested by NcoI and XhoI restriction enzymes to be inserted into the 
pET-28b(+) expression vector and then transformed into RosettaTM E.Coli cells. 
After growing colonies of RosettaTM cells colony PCR was employed to screen 
whether the genes had been inserted to the expression vector and transformed into the cells.  
Seven of the eight genes were effectively transformed in the cells.  Table 1 contains the 
translated sequences for the seven genes. 
P24A04 M K Q W S E V V E L T L G V F V K V H Q R I T Q L I L H L I A Q K L G L N E E A I R Q F F E E F E Q R K
P24C06 M K Q W S E L V E K C L L R F V K L H Q R I T Q V K L H S V A Q L L G L N E E A I R Q F F E E F E Q R K
P24G01 M K Q W S E A V E S V L V W F V K N H Q R I T Q P R L H Y V A Q L L G L N E E A I R Q F F E E F E Q R K
P25C02 M K Q W S E A V E D R L G E F V K L H Q R I T Q L R L H F A A Q P L G L N E E A I R Q F F E E F E Q R K
P25E03 M K Q W S E M V E R Q L E S F V K Y H Q R I T Q G F L H M W A Q G L G L N E E A I R Q F F E E F E Q R K
P25G06 M K Q W S E W V E R M L I L F V K L H Q R I T Q V T L H G S A Q P L G L N E E A I R Q F F E E F E Q R K
P25H03 M K Q W S E R V E I W L D V F V K S H Q R I T Q I R L H C Y A Q S L G L N E E A I R Q F F E E F E Q R K  
Table 1.  Selected translated gene sequences for expression.  Variable residue positions highlighted in red. 
Using Crmp2 wildtype protein as a positive control, the genes were induced for 
expression in kanamycin–treated LB media.  Soluble proteins were isolated and visualized on 
a SDS-PAGE electrophoresis gel (Error! Not a valid bookmark self-reference.) and then 
purified using the His6 region conferred from the pET-28b(+) expression vector.  The 
positive control was seen to be purified after His6 purification, but the genes of interest were 
not seen (Figure 13) after running a 8.5% Tricene electrophoresis gel.  The fact that there is 
no expression seen on the SDS-PAGE gels can be explained by a few possibilities.  One, the 
proteins may not be expressed well in the bacterial system used.  Two, because of the small 
size of the protein (between 7.2 and 7.4 kD each) it is possible that after the genes were 
expressed they were degraded before they were isolated and purified.  Three, it could be that 
since the protein is so small that the Coomasie stain is not efficient enough nor reacts well 
enough with the protein’s amino acid composition or amount of expressed protein to 
effectively stain the protein for visualization. 
For future analysis of 3HB gene expression, a couple things could be taken into 
consideration and tried.  A different staining procedure could be used, such as silver staining, 
which is less sensitive to protein composition and amount.  Most likely the issue could be 
overcome by fusing the 3HB gene to a larger stable soluble protein that is expressed well in 
E.Coli.  Upon purification of the fusion protein, cleavage of the 3HB protein from its larger 
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“helper” protein and size exclusion purification could provide isolated expressed 3HB 
protein suitable for further characterization. 
 
1    2    3    4   5   6   7    8    9   10  11 12  13 
80 kD 
Figure 12.  Expression results of 3HB library proteins.  3HB genes (lanes 4-13), even-numbered lanes are soluble 
protein fractions, and wild type Crmp2 (lanes 2-3), 2 is soluble protein fraction.  (Uninduced sample lane 1) 
 
 
Figure 13.  His purified 3HB proteins (lanes 6-11) and wild type Crmp2 (lanes 3-5).  (Uninduced sample lane 2) 
Gene Expression Materials and Methods 
To sequence the amplified library 0.163 µL (0.15 pmol, 15.9 ng) of the library PCR 
product was added to 1 µL DNA blunting enzyme as described in the Fermentas Sticky-end 
Cloning Protocol included in the CloneJETTM PCR cloning kit (Fermentas# K123) to prepare 
the PCR DNA for ligation.  1 µL (50 ng) of pJET1.2 DNA cloning vector was added to the 
ligation mix with 1 µL (5 u) of T4 DNA ligase.  After ligation of the DNA to the 
pJET1.2/blunt vector the clones were transformed into Top10 E. coli cells by adding 10 µL 
1   2   3    4   5   6   7   8   9   10   11
80 kD 
7 kD 
7 kD 
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of the ligation mix to 50 µL of Top10 cells.  The cells were incubated on ice for 5 min then 
heat shocked at 42°C for 45 sec.  The cells were kept on ice for 2 min, then 250 µL of 
lysogeny broth (LB) media was added to the cells, and the cells were incubated at 37°C for 1 
hr in a shaker.  75 µL of the cells were transferred to a Petri dish containing LB media agar 
that had been pre-warmed and treated with carbenicillin, and the cells were incubated 
overnight at 37°C. 
From the plate of growth colonies, 96 colonies were selected for colony PCR.  25 
nmol of the 5’ primer, pJET1.2 forward (5’-CGA CTC ACT ATA GGG AGA GCG GC-3’), 
and 3’ primer, pJET1.2 reverse (5’-AAG AAC ATC GAT TTT CCA TGG CAG-3’) primers 
were used to amplify each colony in a 100 µL reaction with Taq polymerase (NEB).  The 
conditions for colony PCR are as follows: 1) 94°C for 10 min; 2) 94°C for 30 sec, 58°C for 
30 sec, 72°C for 1 min (repeating cycle 30 times); 72°C for 10 min.  These reactions were 
then sent to Beckman Coulter Genomics for sequencing to check the integrity of the 
amplified DNA.   
The sequences from the 96 colony PCR reactions were analyzed, and eight sequences 
were chosen based on sequence integrity to express in RosettaTM E. Coli.  The colony PCR 
products for those eight genes were purified and amplified again using PCR.  1 µL purified 
colony PCR product was added to the reaction mix containing the 5’ primer TLLO-3HB-5-
31 (5’-ATC ACA CAC CAT GGG TAA ACA GTG GAG CGA G-3’) and the 3’ primer 
TLLO-3HBFDB-3-35 (5’-GTA GAA GTC TCG AGT CAA TGA TGA TGA TGA TGA 
TG-3’), and Taq polymerase, and the following conditions were used: 1) 94°C for 2 min; 2) 
94°C for 1 min, 60°C for 40 sec, 72°C for 1 min (repeating cycle 20 times); 72°C for 10 min. 
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50 µL of the amplified genes were digested with 1 µL of the restriction enzymes 
XhoI (NEB# R0146) and NcoI (NEB# R0193) in NEBuffer 2 (NEB# B7002S) in parallel  
with the digestion of 50 µL of the expression vector pET-28b(+) (Novagen# 69865-3) using 
the same enzymes to prepare the genes for insertion into pET-28b(+).  Digestion proceeded 
at 37°C for 3 hr.  The reaction was purified using gel extraction on a 1% low molecular 
weight agarose gel.  Purification proceeded using the QIAquick Gel Extraction Kit from 
QIAgen (QIAgen# 28704).  5µL of the purified genes and 1 µL of the vector were ligated 
together in reactions containing 400,000 U of NEB T4 DNA ligase (NEB# M0202).  The 
ligation reactions were incubated overnight at 16°C. 
The 10µL ligation reactions were added to RosettaTM (DE3) Competent Cells 
(Novagen# 70954) competent cells that had been thawed on ice.  The cells and ligation 
reaction were incubated on ice for 5 min.  The cells were heat-shocked for 45 seconds at 
42°C, and then kept on ice for 2 min.  LB media was added to the cells, and the cells were 
shaken for 1 hr at 37°C.  To grow up individual colonies 150 µL of the cells was spread over 
0.1% kanamycin and 0.1% chloramphenicol-treated LB agar plates and incubated overnight 
at 37°C. 
To confirm effective transformation of our plasmid into the RosettaTM cells, one 
colony from each of the agar plates was added to 50 µL of PCR reaction mix containing Taq 
polymerase and 12.5 pmol of the 5’ primer TLLO-3HB-5-31 and 12.5 pmol of the 3’ primer 
TLLO-3HBFDB-3-35.  The colony PCR conditions were as follows: 1) 94°C for 10 min; 2) 
94°C for 30 sec, 58°C for 30 sec, 72°C for 1 min (repeating cycle 30 times); 72°C for 10 
min.  A 2% agarose gel was run to visualize the PCR products (Figure 14). 
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1 2 3 4 
200 bp 
5 6 7 8 
200 bp 
 
Figure 14.  Colony PCR confirming presence of genes of interest.  (Lane 1 = P24A04; Lane 2 = P24C06; Lane 3 = 
P24G01; Lane 4 = P25A05; Lane 5 = P25C02; Lane 6 = P25E03; Lane 7 = P25G06; Lane 8 = P25H03) 
 
One colony per gene was selected from its corresponding agar plate and grown in 5 
mL of 0.1% kanamycin and 0.1% chloramphenicol-treated LB media as well as the positive 
control wild type protein Crmp2, which has been expressed at high levels in our lab, and 
incubated in a shaker overnight at 37°C.  1 mL of each overnight culture was transferred to 5 
mL 0.1% kanamycin and 0.1% chloramphenicol-treated LB media and incubated in a shaker 
at 37°C until it reached an optical density (OD600) of 0.6 in 600 nm wavelength light.  
Expression was induced by adding 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) to 
each culture and incubating in a shaker at 37°C for 2 hr.  Isolation of soluble proteins was 
obtained by transferring 1 mL of each culture to a 1.5 mL microcentrifuge tube.  Each culture 
was centrifuged at 14,000 rpm for 1 min, and the supernatant was removed and discarded.  
The pellets were resuspended in 400 µL of 50 mM HEPES containing 150 mM NaCl.  Each 
resuspended pellet was sonicated for 10 sec and put on ice immediately.  Each tube was 
centrifuged at 14,000 rpm for 2 min at 4°C, and the supernatant was transferred to a new 1.5 
mL microcentrifuge tube.  A 12% SDS-PAGE gel was run and stained in Coomasie blue to 
check the expression level of the genes.  There was no visible expression of the genes of 
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interest or positive control.  The same protocol as above was followed to obtain cell cultures 
of OD600 of 0.6, but this time 0.5 mM IPTG was added to each culture, and the cultures were 
shaken overnight at 20°C.  An 8.5% tricene gel was run and stained in Coomasie blue to 
visualize expression. 
His purification was performed on wildtype Crmp2 along with two 3HB proteins.  25 
µL of TALON® Metal Affinity Resin (Clontech# 63550) was added to the supernatant from 
the previous protein isolation.  The tubes were rotated for 30 min at room temperature and 
centrifuged at 3000 rpm for 1 min.  The supernatant was removed.  The beads were washed 
three times with 50 mM HEPES containing 50 mM NaCl and 10 mM imidazole, then 
centrifuged at 3000 rpm for 1 min for each wash.  After each wash the supernatant was 
transferred to a new 1.5 mL microcentrifuge tube.  After washing the proteins were removed 
from the beads by adding 50 mM HEPES containing 50 m NaCl and 100 mM imidazole and 
centrifuging at 3000 rpm for 1 min three times.  The supernatant was transferred to a new 1.5 
mL microcentrifuge tube after each centrifugation.  The eluted fractions for each protein 
were run on a 12.5% SDS-PAGE gel and stained in Coomasie blue to visualize the presence 
of purified protein. 
 
 
 
 CHAPTER 4 
pGFP-3HB Sequence Analysis Results 
From kanamycin and IPTG-treated LB agar plates containing pGFP-3HB expressing 
E.Coli received from Jianwei Zhou, 825 colonies were chosen based on their relative 
fluorescent intensities (453 of 100% relative intensity, 168 of 50% relative intensity, and 204 
of less than 20% relative intensity) and grown in kanamycin-treated LB media.  With each 
culture representing a different gene, their 3HB library genes were amplified and sequenced.  
In total, 266 unique sequences were identified of 100% relative intensity, 72 unique 
sequences of 50% relative intensity, and 117 unique sequences of less than 20% relative 
intensity.  After sequencing, cultures representing each unique gene sequence were plated on 
kanamycin and IPTG-treated LB agar plates to exhibit the relative intensities associated with 
each sequence (Figure 15,Figure 16, Figure 17).    From these plates it is clear to see that not 
all of the sequences that correlate to 100% or 50% intensity indeed fluoresce at that intensity.  
In the end only 66 sequences correlated well to 100% intensity and only 17 sequences 
correlated well to 50% intensity.  Table 2 provides an analysis of the differences between 
intensity and variable position.  Appendix 1 includes all of the unique sequences that 
correlate well to their respective fluorescent intensities. 
From Table 2 it appears that there are some preferences in primary structure for 
highly stable proteins that yield maximum fluorescence.  For example in variable position 
one glutamate appears in 23% of the sequences.  At position two, glycine is present in 21% 
of the sequences.  At position three, serine and lysine appear in a combined 30% of 
sequences.  At position four, tyrosine and serine are the only amino acids that appear in more 
than 10% of sequences at 14% and 17%, respectively.  Arginine appears in 21% of the 
sequences at variable position five with serine appearing in another 12%.  At position six, 
serine appears 20% of the time, while glycine appears 18% and arginine 11%.  At position 
seven, serine appears in 20% of sequences, while no other amino acid appears more than 9%.  
At position eight, glycine, arginine, serine, and glutamate appear in approximately the same 
number of sequences at a higher frequency than the rest of the amino acids, but combined 
arginine, serine, and glutamate are present in 42%.  At position nine, arginine, serine, 
glycine, and leucine all appear more or less at the same frequency with a seeming preference 
over the rest of the amino acids.  At position ten, serine, glutamine, and leucine appear most 
frequently at 15%, 11%, and 11%, respectively.  At position eleven, leucine appears in 17% 
of sequences and serine and valine appear in a combined 23% of sequences.  Because these 
variable residue positions are on the surface of the protein (meaning solvent facing) one 
would expect charged and/or polar amino acids to predominate the selection, but it appears at 
some positions, namely two and eleven, that more aliphatic side chains are preferred or at 
least tolerated to accommodate stable folding of the protein.  The rest of the variable 
positions seem to follow the trend of preferring charged and/or polar residues over non-
charged or non-polar residues. 
It also appears from Table 2 that there are some trends in primary protein structure 
that exist in the less than 20% fluorescent pool.  At position one, glycine is contained in 26% 
of all sequences.  Position two seems to show little or no preference to a particular amino 
acid or class of amino acids.  At position three, valine and leucine both appear in 16% of the 
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sequences.  At position four, leucine and methionine both appear in 19% of sequences.  At 
position five, leucine is contained in 21% of sequences, while valine and tryptophan 
combined appear in another 26% of sequences.  Position six seems to favor leucine to a 
certain degree (15%).  Position seven seems to follow the same trend as position six, namely 
leucine is preferred (15%).  At position eight, leucine and valine appear in 24% and 13% of 
sequences, respectively.  At position nine, leucine appears in 27% of sequences, and glycine 
and valine are included in another 23%.  At position ten, leucine and tryptophan combined 
appear in 26% of sequences.  At position eleven, leucine and valine appear in 15% and 12% 
of sequences, respectively. 
pGFP-3HB Sequence Analysis Materials and Methods 
Assembly of the 3HB library with the GFP encoding gene (courtesy of Dr. Geoffrey 
S. Waldo), ligation of the new library into the pET-28b(+) vector, transformation into 
RosettaTM cells, and expression on agar plates containing IPTG were performed by Jianwei 
Zhou.  Colonies from each expression plate were visualized under 365 nM UV light and 
assigned a relative intensity value.  861 fluorescent colonies (453 of approximately 100% 
intensity, 204 of approximately 50% intensity, and 204 of approximately less than 20% 
intensity) were chosen and grown in LB media containing 0.1% kanamycin overnight.  Half 
of the culture was removed and stored in a 25% glycerol solution and stored at -80°C.  Each 
culture was subjected to colony PCR to amplify and screen the 3HB genes using the 
following conditions: 1) 94°C for 10 min; 2) 94°C for 30 sec, 58°C for 30 sec, 72°C for 1 
min (repeating cycle 30 times); 72°C for 10 min.  The PCR reactions were sent to Beckman 
Coulter genomics for sequencing.  For each unique sequence 0.2 µL of glycerol stock cells 
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was plated onto a kanamycin-treated agar plate containing 1mM IPTG in a grid-like fashion 
for direct comparison of intensity.  
The raw sequencing data was first imported into Sequencher® (10) where the 
sequences were aligned and trimmed.  The sequences were exported in FASTA format and 
translated to their corresponding amino acid sequences using the Sequence Manipulation 
Suite: Translate online tool (11).  Images were captured using a Canon PowerShot A400 
digital camera. 
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 Figure 15.  100% relative intensity pGFP-3HB colonies with unique sequences. 
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 Figure 16. 50% relative intensity pGFP-3HB colonies with unique sequences. 
 
Figure 17.  15% relative intensity pGFP-3HB colonies with unique sequences. 
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100% 1 2 3 4 5 6 7 8 9 10 11 50% 1 2 3 4 5 6 7 8 9 10 11 15% 1 2 3 4 5 6 7 8 9 10 11
A 3 5 2 5 12 8 8 8 2 3 5 A 12 0 0 0 0 6 0 0 24 6 12 A 3 5 2 3 3 1 5 3 5 8 5
C 3 6 0 6 3 3 0 5 3 5 3 C 6 0 0 0 0 0 6 12 0 0 0 C 2 5 0 2 4 3 3 4 3 3 5
D 8 5 3 6 0 6 8 0 6 6 6 D 0 0 0 0 6 0 6 6 6 0 0 D 3 3 3 2 0 4 5 1 2 1 2
E 23 6 3 2 6 6 6 11 2 3 5 E 12 0 6 6 0 6 6 0 0 0 24 E 7 3 5 3 4 1 2 2 2 3 4
F 3 0 2 3 2 0 2 2 2 3 2 F 0 6 0 12 0 0 0 6 12 6 0 F 2 3 6 9 5 9 5 9 4 4 3
G 17 21 9 9 6 18 9 17 11 5 5 G 18 29 29 12 18 6 0 6 6 6 0 G 26 13 10 7 4 3 3 5 12 7 7
H 2 5 2 3 3 0 2 0 6 3 5 H 0 6 0 6 0 0 0 0 0 12 0 H 3 2 2 3 1 1 0 3 2 3 2
I 2 0 2 3 0 2 2 0 2 0 0 I 0 0 6 0 6 0 0 0 0 6 6 I 1 6 6 4 5 5 4 3 3 2 5
K 0 3 6 2 2 0 3 0 3 2 5 K 0 0 0 6 0 6 0 0 0 12 6 K 0 2 2 1 1 3 4 0 3 2 3
L 6 6 12 3 5 5 8 2 11 11 17 L 6 6 12 0 12 18 18 6 24 12 6 L 7 6 16 19 21 15 15 24 27 13 15
M 2 3 5 2 5 2 5 5 2 9 3 M 0 6 0 6 6 0 0 6 0 0 6 M 1 9 8 19 4 5 9 0 2 3 9
N 0 3 9 5 3 3 2 3 2 0 2 N 6 0 6 0 0 0 0 0 0 0 0 N 3 1 1 2 1 3 4 0 0 1 3
P 3 3 3 5 5 3 5 6 6 6 5 P 0 0 6 0 24 0 6 12 0 0 6 P 3 1 0 1 3 3 4 3 3 3 7
Q 3 6 6 3 5 8 5 3 3 11 3 Q 6 0 0 0 0 6 0 0 0 6 0 Q 1 1 2 1 2 1 3 2 2 3 1
R 6 8 5 5 21 11 2 17 14 5 8 R 12 6 6 0 18 24 18 6 0 18 6 R 10 8 8 3 3 9 7 8 3 9 6
S 9 9 18 14 12 20 20 14 12 15 12 S 6 29 18 12 6 0 12 18 6 0 0 S 9 9 4 3 7 9 3 9 4 9 3
T 2 6 0 0 6 3 8 3 6 3 3 T 0 0 6 0 0 0 0 6 12 6 18 T 1 3 5 2 5 6 5 3 1 1 3
V 5 3 9 3 5 0 6 0 5 6 11 V 0 0 0 24 0 18 29 6 12 0 0 V 9 9 16 9 14 8 9 13 11 9 12
W 5 0 5 8 0 3 2 3 5 3 2 W 18 6 6 12 0 6 0 6 0 12 6 W 9 10 3 3 12 9 6 5 6 13 5
Y 2 3 2 17 2 2 3 5 2 3 3 Y 0 6 0 6 6 6 0 6 0 0 6 Y 2 3 2 8 3 3 3 5 4 4 0  
Table 2.  Comparison of percentage of amino acid residues at variable positions amongst the three intensity groups.  
Top row is variable position number.  Left column of each table section is one letter amino acid abbreviation.  All 
values are percentages of total amino acid count.  (Right side table labeled 15% = less than 20%). 
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 CHAPTER 5 
Discussion 
There has been much attention paid to discovering targeting molecules for drug 
delivery.  These molecules range in size and design.  Engineered protein domains have the 
advantage of being small and very stable and therefore can be used to generate libraries 
based on randomizing amino acids that lie on the binding surface of the protein domain.  
They can possess very high affinity for specific protein targets like antibodies, and they can 
also be assembled in high numbers on the surface of nanoparticles like small molecules.  
With these two features engineered protein domains are potentially very useful molecules. 
The experiments explained herein describe an attempt to analyze a small engineered 
protein domain based on a three helix bundle domain abbreviated 3HB.  It was taken through 
the pre-selection phase of mRNA display to analyze its utility in that process.  While the pre-
selected library was unable to be regenerated in this particular procedure, it is hypothesized 
that an error in reverse transcription prohibited that regeneration and identifying the problem 
within reverse transcription will render the 3HB library amenable to mRNA display selection 
in its entirety.  This hypothesis is based on the observation that FLAG purified fusion 
molecules are present on the SDS-PAGE fluorescence gel, which can occur successfully 
regardless of successful reverse transcription. 
A select set of seven 3HB genes were inserted into pET-28b(+) expression vector and 
were induced to express their respective genes in RosettaTM E.Coli cells.  Expression of these 
proteins was not observed.  It is hypothesized that either the expression system is not suitable 
for expression of such genes, that the proteins expressed are so small that they are degraded 
quickly before it is able to be isolated with other soluble proteins in the bacteria, or that the 
staining method used was not robust enough to visualize the proteins on the gel.  It seems 
possible to express these genes in the future by fusing them with a larger soluble protein and 
then later removing that larger protein to isolate the 3HB domain. 
In conjunction with the experiments mentioned above, the 3HB library was fused to 
GFP to form an expressible reporter gene.  When the 3HB gene folds stably in E.Coli, the 
GFP folds stably and makes expressing bacteria fluorescent.  861 bacterial colonies were 
sequenced and analyzed based on their comparative fluorescent intensities.  Of those 861, 
E.Coli cultures containing the 456 genes with unique sequences were plated on agar plates 
for comparison of intensity.  Of those 456, 200 sequences correlated with their intensity on 
the plates. 
Analysis of the sequences themselves yielded a nice comparison of amino acid 
preference at variable positions in the peptide chain.  There are many factors that could 
influence the overall sequence integrity such as PCR mutation, codon frequency, and 
individual E.Coli reserves, but the sequence analysis appears to support what is typically held 
as expected from stably folding proteins.  The general trend was that charged and polar 
residues at the surface variable positions, in particular serine, arginine, and gluatamate (at 
position one) contributed to greater stability in folding and greater fluorescent intensity, 
while non-charged and non-polar amino acids, namely leucine and valine, were more 
prevalent in sequences that led to less than 20% relative fluorescent intensity and 
consequently less stable protein folding.  In fact, at every variable position in the 100% 
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protein sequences, except position 4, at least 55% of the residues are charged, polar, or 
“special case” amino acids, and at every variable position in the less than 20% sequences at 
least 59% of the residues are non-charged or non-polar amino acids. 
Concluding Remarks 
 With the results from these three different but correlated experiments it’s concluded that 
the 3HB library would be well suited to undergo the mRNA selection process.  With the 
information gleaned from the protein folding stability assay this selection process could be 
even more directed and specific.  With more specificity in an updated design of the 3HB 
library, one could generate a more relevant diversity pool and potentially select more 
therapeutically relevant engineered protein domains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
Appendix 
Unique sequences of 3HB library genes as acquired via the protein folding assay using 
GFP as a reporter.  Sequence names that begin with 100, 50, and 15 indicate 100%, 50%, and 
less than 20% relative intensity, respectively. 
100_1_C5 M K Q W S E H V E D M L S Q F V K G H Q R I T Q T F L H N Q A Q R L G L N E E A I R Q F F E E F E Q R K
100_1_C9 M K Q W S E L V E W K L H G F V K A H Q R L T Q D E L H R L A Q E L G L N E E A I R Q F L E E F E Q R K
100_1_D1 M K Q W S E L V E R S L W G F V K S H Q R I T Q D W L H G T A Q S L G L N E E A I R Q F F E E F E Q R K
100_1_D3 M K Q W S E S V E Q R L V P F V K R H Q R I T Q H V L H I Y A Q N L G L N E E A I R Q F F E E F D Q R K
100_1_D6 M K Q W S E V V E G G L A Y F V K T H Q R I T Q Y E L P S V A Q M L G L N E E A I R Q F F E E F E Q R K
100_1_D7 M K Q W S E P V E G S L C L F V K D H Q R I T Q T G L H A S A Q P L G L N E E A I R Q F F E E F E Q R K
100_1_D11 M K Q W S E M V E R G L W R F V K L H Q R I T Q D Y L H S Q A Q H L G L N E E A I R Q F F E E F E Q R K
100_1_E5 M K Q W S E G V E G V L W L F V K S H Q R I T Q A G L H V L A Q R L G L N E E A I R Q F F E E F E Q R K
100_1_E6 M K Q W S E E V E S V L G M F V K G H Q R I T Q A R L H P M A Q S L G L N E E A I R Q F F E E F E Q R K
100_1_E12 M K Q W S E S V E G V L D T F V K E H Q R I T Q P W L H G L A Q F L G L N E E A I R Q F F E E F E Q R K
100_1_F3 M K Q W S E R V E P N L F G F V K S H Q R I T Q S R L H D S A Q L L G L N E E A I R Q F F E E F E Q R K
100_1_F10 M K Q W S E W V E G G L V G F V K G H Q R I T Q E G L H G G A Q E L G L N E E A I R Q F F E E F E Q R K
100_1_G5 M K Q W S E G V E S L L V P F V K R H Q R I T Q G G L H G G A Q D L G L N E E A I R Q F F E E F E Q R K
100_1_G6 M K Q W S E G V E H L L D N F V K G H Q R I T Q L L L H D W A Q R L G L N E E A I R Q F F E E F E Q R K
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15_1_F7 M K Q W S E G V E W W L S T F V K S R Q R I T Q L P L H A C A Q A L G L S E E A I R Q F F E E F E Q R R  
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15_1_F8 M K Q W S E G V E W W L V T F V K G H Q R I T Q M V L H E W A Q A L G L N E E A I R Q F F E E F E Q R K
15_1_F9 M K Q W S E W V E R G L M V F V K S H Q R I T Q M L L H G R A Q V L G L N E E A I R Q F F E E F E Q R K
15_1_F10 M K Q W S E W V E G L L M L F V K R H Q R I T Q G V L H G G A Q V L G L N E E A I R Q F F E E F E Q R K
15_1_F11 M K Q W S E W V E G S L M A F V K W H Q R I T Q L V L H L I A Q W L G L N E E A I R Q F F E E F E Q R K
15_1_F12 M K Q W S E G V E W G L M A F V K W H Q R I T Q M A L H G W A Q V L G L N E E A I R Q F F E E F E Q R K
15_1_G1 M K Q W S E G V E W R L M L F V K C H Q R I T Q M F L H G W A Q V L G L N E E A I R Q F F E E F E Q R K
15_1_G2 M K Q W S E G V E W R L M L F V K W H Q R I T Q M F L H G R A Q V L G L N E E A I R Q F F E E F E Q R K
15_1_G3 M K Q W S E R V E G M L L I F V K R H Q R I T Q M L L H V G A Q V L G L N E E A I R Q F F E E F E Q R R
15_1_G4 M K Q W S E G V E G M L L L F V K I H Q R I T Q L I L H A R A Q G L G L N E E A I R Q F F E E F E Q R K
15_1_G5 M K Q W S E D V E Q L L Q V F V K F H Q R I T Q R Y L H L Y A Q F L G L N E E A I R Q F F E E F E Q R K
15_1_G6 M K Q W S E N V E V A L H M F V K N H Q R I T Q R F L H K Q A Q P L G L N E E A I R Q F F E E F E Q R K
15_1_G7 M K Q W S E S V E V W L A S F V K V H Q R I T Q V S L H W Y A Q A L G L N E E A I R Q F F E E F E Q R K
15_1_G8 M K Q W S E L V E G R L V L F V K R H Q R I T Q C C L H L P A Q M L G L N E E D I R Q F F E E F E Q R K
15_1_G9 M K Q W S E G V E E G L L V F V K M H Q R I T Q Q R L H W V A Q E L G L N E E A I R Q F F E E F E Q R K
15_1_G10 M K Q W S E M V E G L L F W F V K I H Q R I T Q R D L P Y G A Q I L G L N E E A I R Q F F E E F E Q R K
15_1_G11 M K Q W S E V V E R I L V G F V K M H Q R I T Q A W L H P P A Q R L G L N E E A I R Q F F E E F E Q R K
15_1_G12 M K Q W S E L V E H V L Y C L V K P H Q R I T Q K L L H L F A Q S L G L N E E A I R Q F F E E F E Q R K
15_1_H1 M K Q W S E G V E G V L M W F V K L H Q R I T Q V G L H L S A Q M L G L N E E A I R Q F F E E F E Q R K
15_1_H2 M K Q W S E Q V E A E L Y W F V K D H Q R I T Q D W L H L A A Q L L G L N E E V I R Q F F E E F E Q R K
15_1_H3 M K Q W S E E V E I V L M W F V K L H Q R I T Q M C L H P Y A Q L L G L N E E A I R Q F F E E F E Q R K
15_1_H4 M K Q W S E V V E D A L L E F V K Y H Q R I T Q P S L H Q S A Q E L G L N E E A I R Q F F E E F E Q R K
15_1_H5 M K Q W S E E V E E V L F R F V K M H Q R I T Q A C L H L E A Q G L G L N E E A I R Q F F E E F E Q R K
15_1_H6 M K Q W S E D V E G M L I V F M K S H Q R I T Q L V L H A V A Q K L G L N K E A I R Q F F E E F E Q R K
15_1_H7 M K Q W S E S V E V I L S P F V K L H Q R I T Q L H L H V N A Q W L G L N E E A I R Q F F E E F E Q R K
15_1_H8 M K Q W S E S V E S R L F W F V K C H Q R I T Q N L L H L S A Q L L G L N E E A I R Q F F E E F E Q R K
15_1_H9 M K Q W S E R V E Y Q L F V F V K V H Q R I T Q L L L H W G A Q L L G L N E E A I R Q F F E E F E Q R K
15_1_H10 M K Q W S E V V E G T L V T F V K L H Q R I T Q Y E L H G L A Q W L G L N E E A I R Q F F E E F E Q R K
15_1_H11 M K Q W S E G V E D V L L W F V K F H Q R I T Q W Q L H F V A Q V L G L N E E A I R Q F F E E F E Q R K
15_1_H12 M K Q W S E G V E V V L V W F V K M H Q R I T Q A R L H W A A Q M L G L N E E A I R Q F F E E F E Q R K
15_2_A1 M K Q W S E G V E M V L M W F V K S H Q R I T Q V R L H V L A Q M L G L N E E A I R Q F F E E F E Q R K
15_2_A2 M K Q W S E W V E C Y L E L F V K V H Q R I T Q D L L H L K A Q D L D L N E K T I R Q F F K E F K H R K
15_2_A3 M K Q W S E G V E R W L G L F V K R H Q R I T Q V R L H V W A Q L L G L N E E A I R Q F F E E F E Q R K
15_2_A4 M K Q W S E G V E M V L F F F V K L H P R I T Q L L L H E M A Q T L G L N E E A I R Q F F E E F E Q R K
15_2_A5 M K Q W S E G V E M V L I C F V K S H Q R I T Q P Q L H V V A Q M L G L N E E A I R Q F F E E F E Q R K
15_2_A6 M K Q W S E S V E R K L L C F V K S H Q R I T Q N T L H V L A Q V L G L N E E A I R Q F F E E F E Q R Q
15_2_A7 M K Q W S E S V E L R L M V F V K V H Q R I T Q R P L H L A A Q P L G L N E E A I R Q F F E E F E Q R K
15_2_A8 M K Q W S E P V E I L L V S F V K S H Q R I T Q I S L H G Q A Q L L G L N E E A I R Q F F E E F E Q R K
15_2_A9 M K Q W S E A V E V G L C E F V K Y H Q R I T Q M W L H V A A Q I L S L N E E A I R Q F F E E F E Q R K
15_2_A10 M K Q W S E G V E I M L Y I F V K T H Q R I T Q F R L H F F A Q H L G L N E E A I R Q F F E E F E Q R K
15_2_A11 M K Q W S E F V E W D L R F F V K R H Q R I T Q F V L H L E A Q R L G L N E E A I R Q F F E E F E Q G K
15_2_A12 M K Q W S E A V E F T L M W F V K L H Q R I T Q L S L H S L A Q I L G L N E E A I R L F F E E F E Q R K
15_2_B1 M K Q W S E D V E I V L Y L F V K D H Q R I T Q W R L H C F A Q L L G L N E E T I R Q F F E E F E Q R K
15_2_B2 M K Q W S E E V E W L L F F F V K F H Q R I T Q P V L H R C A Q C L G L N E E A I R Q F F E E F E Q R K
15_2_B3 M K Q W S E V V E V M L L S F V K L H Q R I T Q D F L H S E A Q K L G L N E E A I R Q F F E E F E Q R K
15_2_B4 M K Q W S E G V E E G L E R F V K T H Q R I T Q G L L H W G A Q E L G L N E E G I R Q F F E E F E Q R K
15_2_B5 M K Q W S E E V E S E L V L F V K S H Q R I T Q I L L H L M A Q I L G L N E E A I R Q F F E E F E Q R K
15_2_B6 M K Q W S E G V E V S L T L F V K K H Q R I T Q S T L H C A A Q R L G L N E E A I R Q F F E E F E Q R K
15_2_B7 M K Q W S E G V E V V L G L F V K N H Q R I T Q W R L H L L A Q G L G L N E E A I R Q F F E E F E Q R K
15_2_B8 M K Q W S E G V E I I L L T F V K L H Q R I T Q T S L H K P A Q S L G L N E E A I R Q F F E E F E Q R K
15_2_B9 M K Q W S E E V E I V L N N F V K D H Q R I T Q F L L H I L A Q E L G L N E E A I R Q F F E E F E Q R K  
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